Table of Contents
Pathology Research International
Volume 2015, Article ID 132326, 12 pages
http://dx.doi.org/10.1155/2015/132326
Research Article

Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences

1Laboratory of Recognition and Biological Activity Assays, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
2Laboratory of Biochemistry, Department of Quality Control, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
3Process Development Direction, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
4Department of Cell Biology and Tissues Banking, National Institute of Oncology and Radiobiology, 29 and F Street, Vedado, Plaza de la Revolución, 10400 Havana, Cuba
5Tumor Immunology Direction, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
6Department of Pathology, Manuel Fajardo General Hospital, Zapata and D Street, Vedado, Plaza de la Revolución, 10400 Havana, Cuba
7Clinical Trials Direction, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba
8Research and Development Direction, Center of Molecular Immunology, 216 Street and 15th Avenue, Atabey, Playa, P.O. Box 16040, 11600 Havana, Cuba

Received 8 July 2015; Accepted 16 September 2015

Academic Editor: Marco Volante

Copyright © 2015 Rancés Blanco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Barzi and N. A. Pennell, “Targeting angiogenesis in non-small cell lung cancer: agents in practice and clinical development,” European Journal of Clinical and Medical Oncology, vol. 2, no. 1, pp. 31–42, 2010. View at Google Scholar · View at Scopus
  2. K. Kaira, N. Oriuchi, N. Sunaga, T. Ishizuka, K. Shimizu, and N. Yamamoto, “A systemic review of PET and biology in lung cancer,” American Journal of Translational Research, vol. 3, no. 4, pp. 383–391, 2011. View at Google Scholar · View at Scopus
  3. X. Jin, Z. Wang, L. Qiu et al., “Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer,” Cancer Science, vol. 99, no. 3, pp. 582–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. Y. Qiu, H. Yang, H. Chen et al., “Detection of CEA mRNA, p53 and AE1/AE3 in haematoxylin-eosin-negative lymph nodes of early-stage non-small cell lung cancer may improve veracity of N staging and indicate prognosis,” Japanese Journal of Clinical Oncology, vol. 40, no. 2, pp. 146–152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. R. Blanco, C. E. Rengifo, M. Cedeño, M. Frómeta, and E. Rengifo, “Flow cytometric measurement of aneuploid DNA content correlates with high S-phase fraction and poor prognosis in patients with non-small-cell lung cancer,” ISRN Biomarkers, vol. 2013, Article ID 354123, 8 pages, 2013. View at Publisher · View at Google Scholar
  6. A. M. Vázquez, M. Alfonso, B. Lanne et al., “Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids,” Hybridoma, vol. 14, no. 6, pp. 551–556, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Hayashi, H. Chiba, K. Kuronuma et al., “Detection of N-glycolyated gangliosides in non-small-cell lung cancer using GMR8 monoclonal antibody,” Cancer Science, vol. 104, no. 1, pp. 43–47, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Blanco, C. E. Rengifo, M. Cedeño et al., “Immunodetection of N-glycolyl GM3 ganglioside inlung carcinoma by immunohistochemistry: a technical study using frozen and formalin-fixed and paraffin-embedded tissues,” Acta Microscopica, vol. 23, no. 3, p. 199, 2014. View at Google Scholar
  9. H. Van Cruijsen, M. Ruiz, P. van der Valk, T. D. de Gruijl, and G. Giaccone, “Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer,” BMC Cancer, vol. 9, article 180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Blanco, C. E. Rengifo, M. Cedeño, M. Frómeta, E. Rengifo, and A. Carr, “Immunoreactivity of the 14F7 Mab (raised against N-glycolyl GM3 ganglioside) as a positive prognostic factor in non-small-cell lung cancer,” Pathology Research International, vol. 2012, Article ID 235418, 12 pages, 2012. View at Publisher · View at Google Scholar
  11. A. Carr, A. Mullet, Z. Mazorra et al., “A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors,” Hybridoma, vol. 19, no. 3, pp. 241–247, 2000. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Ozawa, I. Kawashima, and T. Tai, “Generation of murine monoclonal antibodies specific for N-glycolylneuraminic acid-containing gangliosides,” Archives of Biochemistry and Biophysics, vol. 294, no. 2, pp. 427–433, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. J. de Leòn, A. Fernández, C. Mesa, M. Clavel, and L. E. Fernández, “Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells,” Cancer Immunology, Immunotherapy, vol. 55, no. 4, pp. 443–450, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. J. de León, A. Fernández, M. Clavell et al., “Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25 effector and naturally occurring CD4+CD25+ regulatory T cells function,” International Immunology, vol. 20, no. 4, pp. 591–600, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. T. Lahera, A. Calvo, G. Torres et al., “Prognostic role of 14F7 Mab immunoreactivity against N-glycolyl GM3 ganglioside in colon cancer,” Journal of Oncology, vol. 2014, Article ID 482301, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Pérez, “Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity,” Immunotechnology, vol. 3, no. 1, pp. 71–81, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. F. M. Freyre, J. Vázquez, C. Duarte, E. Ferrá, I. López, and N. Arteaga, “Anticuerpos monoclonales que reconocen los factores de crecimiento epidérmico humano y murino,” Interferón y Biotecnología, vol. 6, no. 1, pp. 32–46, 1989. View at Google Scholar
  18. E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959. View at Publisher · View at Google Scholar · View at Scopus
  19. C. E. Rengifo, R. Blanco, D. Blanco, M. Cedeño, M. Frómeta, and E. R. Calzado, “Immunohistochemical characterization of three monoclonal antibodies raised against the epidermal growth factor and its receptor in non-small-cell lung cancer: their potential use in the selection of patients for immunotherapy,” Journal of Biomarkers, vol. 2013, Article ID 627845, 9 pages, 2013. View at Publisher · View at Google Scholar
  20. M. Kotani and T. Tai, “An immunohistochemical technique with a series of monoclonal antibodies to gangliosides: their differential distribution in the rat cerebellum,” Brain Research Protocols, vol. 1, no. 2, pp. 152–156, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. C. J. L. Murray and A. D. Lopez, “Measuring the global burden of disease,” The New England Journal of Medicine, vol. 369, no. 5, pp. 448–457, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Berghmans, M. Paesmans, and J.-P. Sculier, “Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables,” Therapeutic Advances in Medical Oncology, vol. 3, no. 3, pp. 127–138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Zalcman, E. Bergot, and E. Lechapt, “Update on nonsmall cell lung cancer,” European Respiratory Review, vol. 19, no. 117, pp. 173–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Marulli, E. Verderi, A. Zuin et al., “Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection,” Interactive CardioVascular and Thoracic Surgery, vol. 19, no. 2, pp. 256–262, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Okamura, K. Takayama, K. Kawahara et al., “PICT1 expression is a poor prognostic factor in non-small cell lung cancer,” Oncoscience, vol. 1, no. 5, pp. 375–382, 2014. View at Publisher · View at Google Scholar
  26. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Global cancer statistics, 2002,” CA: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R.-P. Perng, C.-Y. Chen, G.-C. Chang et al., “Revisit of 1997 TNM staging system—survival analysis of 1112 lung cancer patients in Taiwan,” Japanese Journal of Clinical Oncology, vol. 37, no. 1, pp. 9–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Tabata, T. Tanaka, T. Hayashi et al., “Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered,” BMC Clinical Pathology, vol. 14, article 23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Noguchi, T. Suzuki, K. Kabayama et al., “GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer,” Cancer Science, vol. 98, no. 10, pp. 1625–1632, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. N. Malykh, R. Schauer, and L. Shaw, “N-glycolylneuraminic acid in human tumours,” Biochimie, vol. 83, no. 7, pp. 623–634, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Yin, A. Hashimoto, M. Izawa et al., “Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells,” Cancer Research, vol. 66, no. 6, pp. 2937–2945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Marquina, H. Waki, L. E. Fernández et al., “Gangliosides expressed in human breast cancer,” Cancer Research, vol. 56, no. 22, pp. 5165–5171, 1996. View at Google Scholar · View at Scopus
  33. F. Varghese, A. B. Bukhari, R. Malhotra, and A. De, “IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples,” PLoS ONE, vol. 9, no. 5, Article ID e96801, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. L. L. de Matos, D. C. Trufelli, M. G. L. de Matos, and M. A. da Silva Pinhal, “Immunohistochemistry as an important tool in biomarkers detection and clinical practice,” Biomark Insights, vol. 5, pp. 9–20, 2010. View at Google Scholar
  35. X. Zhao, W. Dai, H. Zhu et al., “Epidermal growth factor (EGF) induces apoptosis in a transfected cell line expressing EGF receptor on its membrane,” Cell Biology International, vol. 30, no. 8, pp. 653–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. D. Siegelin and A. C. Borczuk, “Epidermal growth factor receptor mutations in lung adenocarcinoma,” Laboratory Investigation, vol. 94, no. 2, pp. 129–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  37. E. G. Bremer, J. Schlessinger, and S. Hakomori, “Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor,” The Journal of Biological Chemistry, vol. 261, no. 5, pp. 2434–2440, 1986. View at Google Scholar · View at Scopus
  38. D.-M. Li and H. Sun, “PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15406–15411, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. H.-J. Choi, T.-W. Chung, S.-K. Kang et al., “Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression—transcriptional induction of p21WAF1 and p27kip1 by inhibition of PI-3K/AKT pathway,” Glycobiology, vol. 16, no. 7, pp. 573–583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. Ü. Coskun, M. Grzybek, D. Drechsel, and K. Simons, “Regulation of human EGF receptor by lipids,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 22, pp. 9044–9048, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. O. I. Kostyleva, E. S. Gerstein, A. I. Dykhno, A. V. Vasil'ev, B. E. Polotskiĭ, and N. E. Kushlinskiĭ, “EFR-like peptides and their receptors as prognostic factors for the survival of patients with non-small-cell lung cancer,” Voprosy Onkologii, vol. 45, no. 6, pp. 617–622, 1999. View at Google Scholar · View at Scopus
  42. A. González, A. Carr, K. León et al., “Pharmaceutical compositions for the treatment of tumours that express EGFR and ganglioside N-glycolyl GM3 (NeuGcGM3) (WO 2013097834 A1),” http://www.google.com/patents/WO2013097834A1?cl=es.